Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Up 50.0% in August

Key Points

• Short Interest Growth: Orion OYJ saw a 50% increase in short interest in August, rising to 600 shares from 400 shares, indicating growing bearish sentiment among investors.
• Stock Performance: ORINY stock opened at $38.95 with a market capitalization of $10.99 billion, a PE ratio of 26.50, and has fluctuated between $21.95 and $41.60 over the past year.
• Analyst Ratings: Zacks Research downgraded Orion OYJ from a "strong-buy" to a "hold" rating, and the stock currently has a consensus rating of "Hold" from analysts.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 600 shares, an increase of 50.0% from the August 15th total of 400 shares. Currently, 0.0% of the company's stock are sold short. Based on an average trading volume of 400 shares, the days-to-cover ratio is currently 1.5 days. Based on an average trading volume of 400 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.0% of the company's stock are sold short.

Analysts Set New Price Targets

Separately, Zacks Research downgraded Orion OYJ from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 8th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold".

Orion OYJ Price Performance

Shares of ORINY stock remained flat at $38.95 during trading hours on Friday. The stock had a trading volume of 35 shares, compared to its average volume of 228. Orion OYJ has a one year low of $21.95 and a one year high of $41.60. The company has a quick ratio of 1.05, a current ratio of 1.86 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $10.99 billion, a PE ratio of 26.50 and a beta of 0.11. The business's fifty day simple moving average is $39.54 and its two-hundred day simple moving average is $34.72.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Friday, July 18th. The company reported $0.33 earnings per share (EPS) for the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. The business had revenue of $472.57 million for the quarter. As a group, research analysts expect that Orion OYJ will post 1.18 EPS for the current fiscal year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.